Who makes Tiropramide HCl 100mg?

Tiropramide HCl 100mg is developed by Daewoong Pharmaceutical Co. LTD..

What development phase is Tiropramide HCl 100mg in?

Tiropramide HCl 100mg is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Tiropramide HCl 100mg

Daewoong Pharmaceutical Co. LTD. · FDA-approved active Small molecule Quality 0/100

Tiropramide HCl 100mg, marketed by Daewoong Pharmaceutical Co. LTD., holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not provided. The primary risk is the potential for increased competition post-patent expiry in 2028.

At a glance

Generic name	Tiropramide HCl 100mg
Sponsor	Daewoong Pharmaceutical Co. LTD.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tiropramide HCl 100mg CI brief — competitive landscape report
Tiropramide HCl 100mg updates RSS · CI watch RSS
Daewoong Pharmaceutical Co. LTD. portfolio CI